Patients with Early-Stage Myelodysplastic Syndromes Show Increased Frequency of CD4+CD25high+CD127low Regulatory T Cells
Acta Haematologica, 08/10/2012
Fozza C et al. – The data point to impaired anti–tumor immunity in patients with myelodysplastic syndromes (MDS), even in the early stage, which has already been noted in other clonal disorders.



